Shareholders Fight Amgen's Stay Bid

Law360, New York (January 14, 2010, 5:57 PM EST) -- A group of shareholders that claims Amgen Inc. misled investors by concealing the results of a clinical study involving two of its top-selling anemia drugs has challenged the biotech company’s bid to stay the proceedings while its appeal of an order granting class certification is pending.

In a scathing filing Monday in the U.S. District Court for the Central District of California, lead shareholder Connecticut Retirement Plans and Trust Funds said the “drastic step of imposing a stay” hadn’t been justified, arguing instead that merits deposition...
To view the full article, register now.